|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
C07 BX06
|
|
gptkbp:casnumber
|
1052024-44-8
|
|
gptkbp:clinical_trial
|
Phase 3
ATTR-ACR
ATTR-ACT
ATTR-CM
ATTR-ACT2
|
|
gptkbp:contraindication
|
hypersensitivity to tafamidis
|
|
gptkbp:dosage_form
|
20 mg once daily
|
|
gptkbp:effective_date
|
2019-05-03
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vyndaqel
|
|
gptkbp:indication
|
hereditary transthyretin amyloidosis
wild-type transthyretin amyloidosis
|
|
gptkbp:ingredients
|
gptkb:tafamidis
|
|
gptkbp:interacts_with
|
gptkb:warfarin
other anticoagulants
CYP2 C19 inhibitors
CYP3 A4 inducers
|
|
gptkbp:is_a_guide_for
|
gptkb:American_Heart_Association
gptkb:European_Society_of_Cardiology
gptkb:National_Institute_for_Health_and_Care_Excellence
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
stabilizes transthyretin protein
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:structure
|
C19 H20 N2 O4 S
|
|
gptkbp:used_for
|
treatment of transthyretin amyloidosis
|
|
gptkbp:bfsParent
|
gptkb:tafamidis
|
|
gptkbp:bfsLayer
|
7
|